Purpose: To evaluate the role of adjuvant mitomycin‐C (MMC) use in cases of recurrent rhegmatogenous retinal detachment (RRD) complicated by proliferative vitreoretinopathy (PVR) managed by relaxing retinotomy and retinectomy (RR). Methods: A retrospective analysis of consecutive patients undergoing vitreoretinal surgery with RR for RD and PVR was conducted. Patients were divided into two groups: those receiving 20 μg/0.1 mL MMC via the MMC sandwich method (Group 1) and those who did not (Group 2).Demographics, surgical characteristics, visual outcomes, and complications that may related to MMC were analysed. Results: A total of 28 patients (14 eyes per group) were included in the study. Differences in baseline variables between groups were not significant ( p > 0.05). The mean follow‐up was 15.2 ± 12.2 months. In Group 1, mean preoperative best‐corrected visual acuity (BCVA) improved from 2.72 ± 0.70 logMAR to 1.59 ± 0.61 logMAR postoperatively ( p = 0.001). In Group 2, mean preoperative BCVA increased from 2.06 ± 0.80 logMAR to 1.77 ± 0.94 logMAR ( p = 0.261). Re‐surgery rates were significantly lower in Group 1 (21.4%) than in Group 2 (92.8%, p = 0.001). Final retinal attachment was achieved in 100% of eyes in both groups. Postoperative mean intraocular pressure (IOP) was 16.29 ± 4.46 mmHg in Group 1 and 13.92 ± 1.44 mmHg in Group 2 ( p = 0.081). No MMC‐related toxicity was observed clinically. Conclusions: MMC, applied via the sandwich technique, appears safe and is associated with high anatomical and functional success rates while reducing re‐operations.
Purpose: To investigate the effect of adjuvant mitomycin C (MMC) on severe traumatic retinal detachments (RDs) with advanced proliferative vitreoretinopathy secondary to open-globe injury, managed with relaxing retinotomy and retinectomy. Methods: Medical records of 43 consecutive patients with traumatic RD undergoing relaxing retinotomy and retinectomy between 2016 and 2022 were retrospectively analyzed. Patients were categorized into those who received 20 µg/mL MMC via the MMC sandwich method (group 1) and those who did not (group 2). Preoperative characteristics, surgical interventions, and postoperative outcomes were compared. Results: Group differences in baseline variables were not statistically significant, except for the time interval between trauma and vitrectomy ( P = .018). The mean (±SD) follow-up time was 29.6 ± 10 months. The preoperative best-corrected visual acuity (BCVA) was a median 3.00 logMAR (interquartile range [IQR], 1.00–4.00) in group 1 and 3.50 logMAR (IQR, 1.30–4.00) in group 2. Postoperatively, the median BCVA was 1.85 logMAR (IQR, 0.00–3.00) in group 1 and 3.00 logMAR (IQR, 0.50–4.00) in group 2 ( P < .001). The final sustained retinal attachment rate was 95% in group 1 and 68% in group 2 ( P = .022). The postoperative intraocular pressure was a median 14 mm Hg (IQR, 8–18) in group 1 and 14 mm Hg (IQR, 4–17) in group 2 ( P = .220). There was no MMC-related toxicity observed. Conclusions: MMC can be safely used with the MMC sandwich technique for severe traumatic RDs managed by relaxing retinotomy and retinectomy, with favorable anatomic and functional outcomes despite the small sample size.
14 October 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Background/aim: The aim of the study was to analyze the genotype and phenotype characteristics of Turkish patients with a clinical diagnosis of Stargardt disease and to evaluate how collaboration between the departments of medical genetics and ophthalmology contributes to patient management. Materials and methods: The clinical findings, genetic testing workflow in the medical genetics department, and the genetic testing results of patients clinically diagnosed with Stargardt disease in the ophthalmology department were retrospectively analyzed. Results: The study included 50 patients from 46 families. The genetic test reports confirmed the clinical diagnosis of Stargardt disease type 1 (STGD1) in 27 patients (54%), led to revision of the clinical diagnosis in five patients (10%), and were inconclusive in 18 patients (36%). A total of 26 pathogenic ABCA4 variants were reported in 39 patients, three of which were novel: c.466_467dupAT, p.Leu157SerTer2; c.4540-1G>C; c.878delC, p.Met293SerfsTer7. The most recurrent ABCA4 variant was c.5882G>A, p.Gly1961Glu detected in 10 unrelated patients. Patients with biallelic severe ABCA4 variants or biallelic loss of function variants had an earlier age of ascertainment (p = 0.024 and p = 0.008, respectively). The mean interval between the referral of patients from the ophthalmology clinic and the first visit with the medical geneticist was 13.8 days, and the mean time to receive genetic test results with posttest counseling was 6.9 months after the first visit. Conclusion: This study serves as a representative example of how genetic testing and a multidisciplinary approach can contribute to management of inherited eye diseases. It also reports three novel ABCA4 variants in Turkish patients with Stargardt disease and describes genotype–phenotype correlations. However, conducting multicenter studies with larger sample sizes from Türkiye will be essential to broaden the spectrum of ABCA4 variants and enhance our understanding of genotype–phenotype relationships.
24 August 2026 in Graefe's Archive for Clinical and Experimental Ophthalmology